Skip to main content
. 2022 Mar 25;5(2):261–270. doi: 10.20517/cdr.2021.100

Figure 2.

Figure 2

Hsa_circ_0020714 may act as a biomarker for resistance to anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) patients. (A) Lung adenocarcinoma. (B) Lung squamous cell carcinoma. **P < 0.01.